Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

The gut microbiome has been shown to influence the response of tumors to anti–PD-1
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …

Despite recent advances in cancer immunotherapy, certain tumor types, such as
Glioblastomas, are highly resistant due to their tumor microenvironment disabling the anti …

The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell
killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell …

T cells are critical effectors of cancer immunotherapies, but little is known about their gene
expression programs in diffuse gliomas. Here, we leverage single-cell RNA sequencing …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …